Ramachandran Radhika, Aathi Muthusankar, Ruban Durairaj D, Piramanyagam Shanmughavel
Department of Bioinformatics, Bharathiar University, Coimbatore-641046, Tamilnadu, India.
National Post- Doctoral Fellow, Membrane Protein Biology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067, India.
Curr HIV Res. 2017;15(4):234-244. doi: 10.2174/1570162X15666170106124216.
The chemokine receptor CCR5 acts as a co-receptor for HIV binding and it is considered as an important target by CCR5 antagonists. Entry inhibitor based microbicides gain much importance nowadays as these drugs act at an early stage of HIV lifecycle and thus hinder the viral replication process in humans. The present study intends to identify a CCR5 antagonist which could be developed as a microbicide using computational approaches.
The pharmacophore modeling and 3D QSAR studies was used to screen CCR5 antagonists with enhanced antagonist activity. The docking studies ranked the compounds according to their binding affinity and molecular dynamics simulation validated the stability of the enzymeligand complex.
A five point pharmacophore hypothesis HHPRR (2 hydrophobic; 1 positively ionisable; 2 aromatic ring) was generated. A statistically significant 3D QSAR model with 3 PLS factors was gen- erated for common pharmacophore hypothesis HHPRR.3 with good correlation coefficient value (R2=0.7483). The docking studies revealed that molecular interaction of CCR5 antagonists having good binding affinity are better than the microbicides taken for this study. The QSAR maps revealed the regions as a combined effect of hydrogen bond donors, hydrogen bond acceptors and hydrophobic groups which denoted the substitution of groups indicating the favorable and unfavorable regions for antagonist activity of hydroxypiperidine derivatives. The docking analysis and molecular dynamics simulation screened and validated CCR5 antagonists.
The present study was successful in identifying a CCR5 antagonist which could be developed as a microbicide.
趋化因子受体CCR5作为HIV结合的共受体,被CCR5拮抗剂视为重要靶点。基于进入抑制剂的杀微生物剂如今变得非常重要,因为这些药物作用于HIV生命周期的早期阶段,从而阻碍人类体内的病毒复制过程。本研究旨在通过计算方法鉴定一种可开发为杀微生物剂的CCR5拮抗剂。
采用药效团建模和三维定量构效关系(3D QSAR)研究来筛选具有增强拮抗剂活性的CCR5拮抗剂。对接研究根据化合物的结合亲和力对其进行排序,分子动力学模拟验证了酶-配体复合物的稳定性。
生成了一个五点药效团假设HHPRR(2个疏水基团;1个可正离子化基团;2个芳香环)。针对共同药效团假设HHPRR.3生成了一个具有3个偏最小二乘(PLS)因子的统计学显著的三维定量构效关系模型,相关系数值良好(R2 = 0.7483)。对接研究表明,具有良好结合亲和力的CCR5拮抗剂的分子相互作用优于本研究中使用的杀微生物剂。定量构效关系图谱揭示了作为氢键供体、氢键受体和疏水基团综合作用的区域,这些区域表示基团的取代,表明了羟基哌啶衍生物拮抗剂活性的有利和不利区域。对接分析和分子动力学模拟筛选并验证了CCR5拮抗剂。
本研究成功鉴定出一种可开发为杀微生物剂的CCR5拮抗剂。